

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2020 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report for 2020 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) (the “**2020 Third Quarterly Report**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the People's Republic of China

29 October 2020

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* *for identification purposes only*

1. IMPORTANT NOTICE

- 1.1 The board of directors (the “**Board**”) and the supervisory committee (the “**Supervisory Committee**”) of the Company and its directors, supervisors and senior management warrant that the 2020 Third Quarterly Report of the Group does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.
- 1.2 All directors of the Company attended the Board meeting to review the 2020 Third Quarterly Report of the Group.
- 1.3 Chen Qiyu, the person in charge of the Company, Guan Xiaohui, the Chief Financial Officer, and Chen Zhanyu, the Director of the Accounting Department (Accounting Officer) duly declare that they warrant the truthfulness, accuracy and completeness of the financial statements contained in the 2020 Third Quarterly Report of the Group.
- 1.4 The 2020 Third Quarterly Report of the Group has not been audited.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1 Major financial information

Unit: Yuan Currency: RMB

	30 September 2020	31 December 2019	Ratio of change (%)
Total assets	80,547,989,215.24	76,119,645,663.32	5.82
Net assets attributable to shareholders of the listed company	33,083,709,544.28	31,888,066,063.03	3.75
	Jan – Sept 2020	Jan – Sept 2019	Period-on-period change (%)
Net cash flow generated from operating activities	2,453,135,520.00	2,328,355,784.17	5.36
	Jan – Sept 2020	Jan – Sept 2019	Period-on-period change (%)
Operating revenue	22,102,744,284.03	21,227,618,679.11	4.12
Net profit attributable to shareholders of the listed company	2,478,980,552.00	2,063,704,147.99	20.12
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	2,059,539,441.46	1,722,388,028.34	19.57
Weighted average return on net assets (%)	7.52	7.21	Increase by 0.31 percentage point
Basic earnings per share (RMB/share)	0.97	0.81	19.75
Diluted earnings per share (RMB/share)	0.97	0.81	19.75

Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Items	Jul – Sept 2020	Jan – Sept 2020
Gain or loss on disposal of non-current assets	59,844,008.57	148,673,855.03
Government grant included in profit or loss for the current period (excluding government grant closely related to the Company's normal operation, and entitled in fixed amounts or quantities on a continuous basis according to national standards)	6,590,725.79	63,073,671.90
Profit or loss arising from changes in the fair value of holding held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities, and investment income from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other debt investments, except effective hedging business related to the Company's normal operations	-21,836,656.22	418,849,091.49
Non-operating income and expenses other than those stated above	-9,365,192.57	-29,708,642.14
Other profit or loss items that fall within the meaning of extraordinary gain or loss	—	-18,528,108.93
Impact on minority interests (after tax)	-13,347,990.54	-44,045,903.53
Effect of income tax	-12,806,024.25	-118,872,853.28
Total	9,078,870.78	419,441,110.54

2.2 Total number of shareholders, the shareholding status of the Top 10 shareholders and the Top 10 tradable shareholders (or unrestricted shareholders) of the Company at the end of the Reporting Period

Unit: Share

Total number of shareholders				324,777		
The shareholding status of the Top 10 shareholders						
Name of shareholders	Shareholding at the end of the period	Percentage (%)	Number of restricted shares held	Shares pledged or locked up		Capacity
				Status	Number	
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	36.60	0	None	0	Domestic non-state owned legal entity
HKSCC NOMINEES LIMITED (Note 1)	551,060,098	21.50	0	Unknown	—	Unknown
CHINA SECURITIES FINANCE CORPORATION LIMITED	38,736,157	1.51	0	None	0	State owned legal entity
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	33,849,388	1.32	0	None	0	Unknown
CHINA LIFE INSURANCE COMPANY LIMITED — TRADITIONAL — ORDINARY INSURANCE PRODUCT — 005L — CT001 SHANGHAI*	26,772,761	1.04	0	None	0	Others
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	0.94	0	None	0	State owned legal entity
ABU DHABI INVESTMENT AUTHORITY	18,510,795	0.72	0	None	0	Overseas legal entity
TAIKANG LIFE INSURANCE CO., LTD. — DIVIDEND — INDIVIDUAL DIVIDEND — 019L — FH002 SHANGHAI*	10,569,000	0.41	0	None	0	Others
CENTRAL BANK OF MALAYSIA	8,766,765	0.34	0	None	0	Unknown
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE 50 TRADED OPEN-END INDEX SECURITIES INVESTMENT FUND*	8,717,381	0.34	0	None	0	Others

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
SHANGHAI FOSUN HIGH TECHNOLOGY (GROUP) COMPANY LIMITED*	938,095,290	RMB ordinary shares	938,095,290
HKSCC NOMINEES LIMITED (Note 1)	551,060,098	Overseas listed foreign shares	551,060,098
CHINA SECURITIES FINANCE CORPORATION LIMITED	38,736,157	RMB ordinary shares	38,736,157
HONG KONG SECURITIES CLEARING COMPANY LIMITED (Note 2)	33,849,388	RMB ordinary shares	33,849,388
CHINA LIFE INSURANCE COMPANY LIMITED — TRADITIONAL — ORDINARY INSURANCE PRODUCT — 005L — CT001 SHANGHAI*	26,772,761	RMB ordinary shares	26,772,761
CENTRAL HUIJIN ASSET MANAGEMENT LTD.*	24,067,700	RMB ordinary shares	24,067,700
ABU DHABI INVESTMENT AUTHORITY	18,510,795	RMB ordinary shares	18,510,795
TAIKANG LIFE INSURANCE CO., LTD. — DIVIDEND — INDIVIDUAL DIVIDEND — 019L — FH002 SHANGHAI*	10,569,000	RMB ordinary shares	10,569,000
CENTRAL BANK OF MALAYSIA	8,766,765	RMB ordinary shares	8,766,765
INDUSTRIAL AND COMMERCIAL BANK OF CHINA — SSE 50 TRADED OPEN-END INDEX SECURITIES INVESTMENT FUND*	8,717,381	RMB ordinary shares	8,717,381
Description of the related relationship or concerted action of the above shareholders	The Company does not know if any related relationship or concerted action exists between the abovementioned shareholders of tradable shares.		
Description of resumed voting rights and shareholdings of holders of preferred shares	Not applicable		

Note 1: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients; shares held by it at the end of the Reporting Period includes 49,603,000 H shares of the Company held by Shanghai Fosun High Technology (Group) Company Limited* (“**Fosun High Tech**”) through it, representing approximately 1.94% of the total share capital of the Company at the end of the Reporting Period;

Note 2: HONG KONG SECURITIES CLEARING COMPANY LIMITED is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

2.3 Total number of preferred shareholders, the shareholding status of the Top 10 preferred shareholders and the Top 10 unrestricted preferred shareholders of the Company at the end of the Reporting Period

Not applicable

3. SIGNIFICANT EVENTS

3.1 Significant changes in major financial statement items and financial indicators of the Group and the reasons thereof

(1) Balance Sheet

Unit: Yuan Currency: RMB

Balance Sheet				
Items	30 September 2020	31 December 2019	Ratio of change	Reasons of changes
Financial assets held for trading	1,016,412,863.26	456,650,637.52	122.58%	Mainly due to the purchase of the shares of BioNTech SE during the Reporting Period
Prepayments	594,704,488.24	415,675,156.23	43.07%	Mainly due to the increase in prepayments for goods during the Reporting Period
Other equity instrument investments	16,208,856.24	107,709,225.73	-84.95%	Mainly due to the disposal of financial assets during the Reporting Period
Long-term deferred expenditures	269,914,243.62	160,688,247.32	67.97%	Mainly due to the increase in renovation projects of leased properties during the Reporting Period
Bills payable	355,538,961.44	244,567,689.32	45.37%	Mainly due to the increased payments by bills during the Reporting Period
Non-current liabilities due within one year	4,278,199,659.78	2,562,263,003.09	66.97%	Mainly due to (1) the reclassification of the RMB3 billion corporate bonds with repurchase option ("16 Fosun Pharma 01") expired on 4 March 2021 to "non-current liabilities due within one year" for accounting during the Reporting Period; (2) the transfer of part of the expired and renewed amount of the RMB1.25 billion corporate bonds with repurchase option ("17 Fosun Pharma 01") on 14 March 2020 from "non-current liabilities due within one year" to "bonds payable" for accounting during the Reporting Period
Other current liabilities	667,693,045.69	248,969,275.20	168.18%	Mainly due to the issuance of super short-term commercial papers by the Company during the Reporting Period
Bonds payable	3,386,675,610.44	5,283,863,183.83	-35.91%	Mainly due to the reclassification of the RMB3 billion corporate bonds with repurchase option ("16 Fosun Pharma 01") to "non-current liabilities due within one year" and the renewal of the RMB1.25 billion corporate bonds ("17 Fosun Pharma 01") during the Reporting Period

(2) Income Statement

Unit: Yuan Currency: RMB

Income Statement				
Items	Jan – Sept 2020	Jan – Sept 2019	Ratio of change	Reasons of changes
Research and development expenses	1,877,700,493.10	1,290,028,940.00	45.55%	Mainly due to the increase in the research and development expenditure in biopharmaceutical drugs, small molecular innovative drugs and imported innovative drugs, and increased investment in innovation incubation platform during the Reporting Period
Credit impairment losses	-54,308,952.12	-28,035,808.23	93.71%	Mainly due to the provision for impairment loss on accounts receivable expected to be unrecoverable based on the credit impairment model
Other gains	241,785,580.17	177,190,761.04	36.45%	Mainly due to the increase in government grants during the Reporting Period
Gains from changes in fair value	3,424,448.30	-130,280,259.91	102.63%	Mainly due to the decline in the price of financial assets held in the same period of last year and the transfer of cumulative fair value changes corresponding to the disposal of financial assets to investment income
Gains from disposal of assets	1,840,134.37	18,274,543.61	-89.93%	Mainly due to the effect of disposal of fixed assets during the Reporting Period
Non-operating revenue	12,558,825.08	60,837,112.62	-79.36%	Mainly due to the effect of payments that are not required to be paid in the same period of last year
Profit or loss attributable to non-controlling interests	270,908,243.26	391,892,841.31	-30.87%	Mainly due to the acquisition of certain minority interests in Breas Medical Holdings AB, Sisram Medical Ltd., Tridem Pharma S.A.S, Suzhou Erye Pharmaceutical Co., Ltd.* and Chongqing Yao Pharmaceutical Co., Ltd.* and the changes in profit or loss in certain non-wholly-owned subsidiaries during the Reporting Period
Other comprehensive income, net of tax	-100,190,979.89	34,958,479.93	-386.60%	Mainly due to the foreign currency translation difference arising from fluctuations in foreign currency exchange rates

(3) Statement of Cash Flow

Unit: Yuan Currency: RMB

Statement of Cash Flow				
Items	Jan – Sept 2020	Jan – Sept 2019	Ratio of change	Reasons of changes
Net cash flow generated from investing activities	-3,584,386,012.17	-2,560,243,375.55	-40.00%	Mainly due to the period-on-period increase in funds paid for investment in fixed assets during the Reporting Period
Net cash flow generated from financing activities	-66,215,438.18	2,663,982,639.53	-102.49%	Mainly due to the receipt of proceeds by the controlling subsidiary Shanghai Henlius Biotech, Inc. in the same period of last year, and the repayment of loans during the Reporting Period
Effects of exchange rate fluctuations on cash and cash equivalents	-132,918,882.81	47,762,255.60	-378.29%	Mainly due to the exchange rate fluctuations during the Reporting Period

3.2 Analysis and explanation of the progress, impact and solution of major events

1. On 30 December 2019, the 2019 third extraordinary general meeting of the Company considered and approved, among other matters, the spin-off of Gland Pharma Limited (“**Gland Pharma**”) and its overseas listing plan. The holding subsidiary Gland Pharma was proposed to be listed on the National Stock Exchange of India Limited and BSE Limited.

During the Reporting Period, Gland Pharma has filed the draft red herring prospectus with the Securities and Exchange Board of India, the National Stock Exchange of India Limited and BSE Limited, in relation to its proposed initial public offering of its shares. As at the end of the Reporting Period, the Company has received the “Letter Regarding the Spin-off and Overseas Listing of Subsidiary by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Guo He Han [2020] No. 417)” from the International Cooperation Division of China Securities Regulatory Commission (“**CSRC**”), pursuant to which, the International Cooperation Division of CSRC has no objection to relevant matters regarding the spin-off and overseas listing of Gland Pharma. The Stock Exchange of Hong Kong Limited has confirmed that the Company may proceed with the spin-off and overseas listing of Gland Pharma. Gland Pharma has received the in-principle approval for the listing on the National Stock Exchange of India Limited and BSE Limited.

As at the end of the Reporting Period, the overseas listing of Gland Pharma is subject to, among other things, the approval of the relevant regulatory authorities in India.

2. Fosun High Tech (and/or by parties acting in concert with it) intended to further increase its shareholding in the Company (including A shares and/or H shares) via the trading system of the Shanghai Stock Exchange (including the Shanghai-Hong Kong Stock Connect) from 19 September 2019 to 18 September 2020, if and where appropriate, and the cumulative total amount thereof shall not be less than RMB100 million. The corresponding increased shareholding percentage shall not in aggregate exceed 2% of the total issued shares of the Company as at 19 September 2019 (i.e. 2,562,898,545 shares, the same for below) (and the aggregate number of shares of the Company to be acquired in the 12-month period shall also not exceed 2% of the total issued shares of the Company).

As at 18 September 2020 (after trading hours), the shareholding increase plan has expired. Fosun High Tech acquired a total of 17,169,500 H shares of the Company for an aggregate amount equivalent to approximately RMB395.38 million since the implementation of the above shareholding increase plan, representing approximately 0.67% of the total issued shares of the Company as at 19 September 2019, and the aggregate number of shares of the Company acquired in the 12-month period did not exceed 2% of the total issued shares of the Company.

3.3 Failure to perform undertakings during the Reporting Period

Not applicable

- 3.4 Warning on any potential loss in the accumulated net profit for the period from the beginning of the year to the end of the next reporting period or any material changes in the accumulated net profit as compared with the corresponding period of the previous year and the reasons thereof

Not applicable

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Legal Representative: **Chen Qiyu**

29 October 2020

Consolidated Balance Sheet (Continued)
30 September 2020

Items	30 September 2020	31 December 2019
Current liabilities:		
Short-term loans	7,702,350,126.97	6,358,286,948.48
Bills payable	355,538,961.44	244,567,689.32
Trade payable	2,517,357,702.27	2,152,746,846.36
Wages payable	738,114,680.28	697,396,874.80
Tax payable	797,057,946.81	759,627,944.44
Other payables	4,296,066,175.61	3,906,223,749.08
Including: Interest payable	—	—
Dividends payable	68,139,100.18	127,956,011.68
Contract liabilities	588,650,704.53	503,683,074.94
Non-current liabilities due within one year	4,278,199,659.78	2,562,263,003.09
Other current liabilities	667,693,045.69	248,969,275.20
Total current liabilities	21,941,029,003.38	17,433,765,405.71
Non-current liabilities:		
Long-term loans	9,025,129,212.24	7,293,043,830.91
Bonds payable	3,386,675,610.44	5,283,863,183.83
Lease liabilities	532,902,704.65	410,188,347.41
Long-term payables	240,975,452.56	251,212,082.14
Deferred income	413,223,317.29	417,345,041.75
Deferred tax liabilities	2,887,846,280.10	2,994,047,852.28
Other non-current liabilities	2,637,217,898.37	2,831,966,595.12
Total non-current liabilities	19,123,970,475.65	19,481,666,933.44
Total liabilities	41,064,999,479.03	36,915,432,339.15
Equity:		
Paid-in capital (or share capital)	2,562,898,545.00	2,562,898,545.00
Capital reserve	11,890,297,296.09	12,143,652,211.28
Less: Treasury shares	—	—
Other comprehensive income	-419,242,238.10	-467,993,508.26
Surplus reserve	2,523,799,886.55	2,523,799,886.55
Unappropriated profits	16,525,956,054.74	15,125,708,928.46
Total equity (or shareholders' interests) attributable to the owners of the parent company	33,083,709,544.28	31,888,066,063.03
Non-controlling interests	6,399,280,191.93	7,316,147,261.14
Total equity (or shareholders' interests)	39,482,989,736.21	39,204,213,324.17
Total liabilities and equity (or shareholders' interests)	80,547,989,215.24	76,119,645,663.32

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Balance Sheet of the Parent Company

30 September 2020

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2020	31 December 2019
Current assets:		
Cash and bank balances	421,891,154.91	905,360,096.42
Financial assets held for trading	—	—
Prepayments	—	—
Other receivables	4,873,575,572.65	4,256,091,375.83
Including: Interest receivable	—	—
Dividends receivable	163,818,799.83	319,536,873.77
Inventories	—	—
Non-current assets due within one year	2,648,000,000.00	3,118,000,000.00
Other current assets	764,469,355.56	418,302,069.82
Total current assets	8,707,936,083.12	8,697,753,542.07
Non-current assets:		
Debt investments	—	—
Long-term equity investments	27,604,521,569.00	26,357,125,003.07
Other equity instrument investments	—	38,245,993.17
Other non-current financial assets	149,407,420.69	137,436,726.04
Fixed assets	6,893,764.92	5,732,888.08
Construction in progress	—	—
Intangible assets	903,987.90	1,238,846.70
Development expenditures	—	—
Goodwill	—	—
Long-term deferred expenditures	—	—
Other non-current assets	5,409,013,289.59	5,295,917,903.19
Total non-current assets	33,170,740,032.10	31,835,697,360.25
Total assets	41,878,676,115.22	40,533,450,902.32

Balance Sheet of the Parent Company (Continued)
30 September 2020

Items	30 September 2020	31 December 2019
Current liabilities:		
Short-term loans	3,090,381,370.78	2,978,641,833.15
Receipts in advance	—	—
Contract liabilities	—	—
Wages payable	93,513,705.64	114,482,383.36
Tax payable	59,879,345.95	43,792,831.63
Other payables	2,294,128,618.25	2,691,156,225.15
Including: Interest payable	—	—
Dividends payable	—	—
Non-current liabilities due within one year	3,528,770,627.31	1,962,094,197.01
Other current liabilities	777,935,094.03	4,781,803.87
Total current liabilities	9,844,608,761.96	7,794,949,274.17
Non-current liabilities:		
Long-term loans	1,088,479,875.00	346,740,000.00
Bonds payable	3,386,675,610.44	5,283,863,183.83
Long-term payables	—	—
Deferred income	25,000.00	250,000.00
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Other non-current liabilities	—	—
Total non-current liabilities	5,626,199,359.23	6,781,872,057.62
Total liabilities	15,470,808,121.19	14,576,821,331.79
Equity:		
Paid-in capital (or share capital)	2,562,898,545.00	2,562,898,545.00
Capital reserve	14,517,778,764.84	14,237,158,322.00
Less: Treasury shares	—	—
Other comprehensive income	-76,735,764.69	-303,728,326.08
Surplus reserve	1,281,449,272.50	1,281,449,272.50
Unappropriated profits	8,122,477,176.38	8,178,851,757.11
Total equity (or shareholders' interests)	26,407,867,994.03	25,956,629,570.53
Total liabilities and equity (or shareholders' interests)	41,878,676,115.22	40,533,450,902.32

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Consolidated Income Statement

January – September 2020

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	July – Sept 2020	July – Sept 2019	Jan – Sept 2020	Jan – Sept 2019
I. Total operating revenue	8,074,579,711.93	7,054,850,058.34	22,102,744,284.03	21,227,618,679.11
Including: Operating revenue	8,074,579,711.93	7,054,850,058.34	22,102,744,284.03	21,227,618,679.11
II. Total operating costs	7,537,653,419.61	6,709,469,373.75	20,562,705,383.07	19,857,997,730.00
Including: Operating costs	3,538,645,465.86	2,937,674,384.28	9,754,517,122.19	8,536,657,487.53
Tax and surcharges	61,678,156.31	53,919,704.29	158,831,186.02	170,438,628.37
Selling and distribution expenses	2,351,014,922.09	2,407,588,465.78	6,282,081,934.47	7,406,036,962.51
General and administrative expenses	714,402,583.14	681,653,157.36	2,002,474,056.77	1,800,645,744.87
Research and development expenses	673,275,023.83	440,645,827.79	1,877,700,493.10	1,290,028,940.00
Finance costs	198,637,268.38	187,987,834.25	487,100,590.52	654,189,966.72
Including: Interest expenses	209,380,625.43	267,342,824.99	637,259,090.84	814,282,689.11
Interest income	51,956,554.57	45,987,049.19	148,392,728.65	132,636,755.70
Plus: Other gains	81,747,423.59	84,990,199.69	241,785,580.17	177,190,761.04
Investment income (“-” indicating loss)	497,193,334.84	492,820,817.87	1,672,907,645.61	1,537,475,096.34
Including: Investment income from associates and joint ventures	433,428,750.13	384,381,017.29	1,085,835,184.68	1,118,502,973.12
Gains from changes in fair value (“-” indicating loss)	-19,969,021.47	-194,390,143.06	3,424,448.30	-130,280,259.91
Credit impairment losses (“-” indicating loss)	-11,544,166.48	-6,117,802.93	-54,308,952.12	-28,035,808.23
Asset impairment losses (“-” indicating loss)	-16,634,382.00	-8,750,217.11	-15,717,230.25	-12,987,296.67
Gains from disposal of assets (“-” indicating loss)	219,144.68	-190,207.72	1,840,134.37	18,274,543.61
III. Operating profit (“-” indicating loss)	1,067,938,625.48	713,743,331.33	3,389,970,527.04	2,931,257,985.29
Plus: Non-operating revenue	3,386,876.47	54,994,149.90	12,558,825.08	60,837,112.62
Less: Non-operating expenses	12,752,069.04	6,237,608.68	42,267,467.22	33,445,400.37
IV. Total profit (“-” indicating total loss)	1,058,573,432.91	762,499,872.55	3,360,261,884.90	2,958,649,697.54
Less: Income tax expenses	218,292,050.07	126,531,824.99	610,373,089.64	503,052,708.24
V. Net profit (“-” indicating net loss)	840,281,382.84	635,968,047.56	2,749,888,795.26	2,455,596,989.30
(i) Classification according to the continuity of operation				
1. Net profit from continuing operation (“-” indicating net loss)	840,281,382.84	635,968,047.56	2,749,888,795.26	2,455,596,989.30
2. Net profit from discontinued operation (“-” indicating net loss)	—	—	—	—
(ii) Classification according to ownership				
1. Net profit attributable to the owners of the parent company (“-” indicating net loss)	764,270,397.73	547,584,301.04	2,478,980,552.00	2,063,704,147.99
2. Profit and loss attributable to non-controlling interests (“-” indicating net loss)	76,010,985.11	88,383,746.52	270,908,243.26	391,892,841.31

Consolidated Income Statement (Continued)

January – September 2020

Items	July – Sept 2020	July – Sept 2019	Jan – Sept 2020	Jan – Sept 2019
VI. Other comprehensive income, net of tax	54,775,747.28	-9,016,755.16	-100,190,979.89	34,958,479.93
Other comprehensive income attributable to the owners of the parent company, net of tax	24,685,826.76	7,142,372.12	-29,477,045.61	35,946,029.37
(i) Other comprehensive income not reclassified subsequently to profit or loss	14,961,357.53	144,152.81	87,712,955.49	-26,694,169.11
1. Changes as a result of remeasurement of net defined benefit plan liability or asset	—	—	—	—
2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	16,990,050.34	—	85,922,577.29	—
3. Changes in fair value of other equity instrument investments	-2,028,692.81	144,152.81	1,790,378.20	-26,694,169.11
4. Changes in fair value of credit risk	—	—	—	—
(ii) Other comprehensive income reclassified subsequently to profit or loss	9,724,469.23	6,998,219.31	-117,190,001.10	62,640,198.48
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	-4,915,538.89	-27,514,726.87	23,042,853.48	-57,540,529.80
2. Difference in translation of foreign currency	14,640,008.12	34,512,946.18	-140,232,854.58	120,180,728.28
Other comprehensive income attributable to non-controlling interests, net of tax	30,089,920.52	-16,159,127.28	-70,713,934.28	-987,549.44
VII. Total comprehensive income	895,057,130.12	626,951,292.40	2,649,697,815.37	2,490,555,469.23
Total comprehensive income attributable to the owners of the parent company	788,956,224.49	554,726,673.16	2,449,503,506.39	2,099,650,177.36
Total comprehensive income attributable to non-controlling interests	106,100,905.63	72,224,619.24	200,194,308.98	390,905,291.87
VIII. Earnings per share:				
(i) Basic earnings per share (yuan/share)	0.30	0.22	0.97	0.81
(ii) Diluted earnings per share (yuan/share)	0.30	0.22	0.97	0.81

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Income Statement of the Parent Company

January – September 2020

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	July – Sept 2020	July – Sept 2019	Jan – Sept 2020	Jan – Sept 2019
I. Operating revenue	4,844,081.72	3,815,974.06	5,040,308.12	5,685,313.69
Less: Operating costs	—	—	—	—
Tax and surcharges	—	1,138,885.77	8,963.90	2,411,699.94
Selling and distribution expenses	—	—	—	—
General and administrative expenses	44,165,513.48	65,458,328.69	104,822,654.98	136,505,943.90
Research and development expenses	—	1,400,270.20	—	2,952,245.60
Finance costs	26,400,024.50	24,847,472.18	126,268,251.08	105,319,187.87
Including: Interest expenses	126,941,169.25	143,806,935.92	384,827,335.81	411,681,720.73
Interest income	91,046,461.54	110,395,009.96	273,171,013.57	300,636,180.35
Asset impairment losses	—	—	—	—
Credit impairment losses	—	—	—	—
Plus: Other gains	6,092,635.26	110,486.49	6,506,673.55	300,849.09
Investment income (“–” indicating loss)	534,410,147.05	438,727,482.59	1,252,044,247.50	1,342,948,533.13
Including: Investment income from associates and joint ventures	534,574,554.44	430,736,612.25	1,245,844,682.12	1,250,403,969.29
Gains on net exposure hedges (“–” indicating loss)	—	—	—	—
Gains from changes in fair value (“–” indicating loss)	—	-14,794,694.59	-3,317,122.82	-36,067,868.78
Gains from disposal of assets (“–” indicating loss)	—	7,349.80	—	7,349.80
II. Operating profit (“–” indicating loss)	474,781,326.05	335,021,641.51	1,029,174,236.39	1,065,685,099.62
Plus: Non-operating revenue	—	—	339,383.21	—
Less: Non-operating expenses	—	—	8,673.30	—
III. Total profit (“–” indicating total loss)	474,781,326.05	335,021,641.51	1,029,504,946.30	1,065,685,099.62
Less: Income tax expenses	—	—	—	—
IV. Net profit (“–” indicating net loss)	474,781,326.05	335,021,641.51	1,029,504,946.30	1,065,685,099.62
(i) Net profit from continuing operation (“–” indicating net loss)	474,781,326.05	335,021,641.51	1,029,504,946.30	1,065,685,099.62
(ii) Net profit from discontinued operation (“–” indicating net loss)	—	—	—	—

Income Statement of the Parent Company (Continued)

January – September 2020

Items	July – Sept 2020	July – Sept 2019	Jan – Sept 2020	Jan – Sept 2019
V. Other comprehensive income, net of tax	10,589,675.45	–30,978,219.40	141,618,144.31	–48,270,519.29
(i) Other comprehensive income not reclassified subsequently to profit or loss	15,158,355.54	—	90,374,944.32	63,047.06
1. Changes as a result of remeasurement of net defined benefit plan liability or asset	—	—	—	—
2. Share of the other comprehensive income of the investee accounted for using equity method which will not be reclassified subsequently to profit or loss	16,990,050.34	—	85,922,577.29	—
3. Changes in fair value of other equity instrument investments	–1,831,694.80	—	4,452,367.03	63,047.06
4. Changes in fair value of credit risk	—	—	—	—
(ii) Other comprehensive income reclassified subsequently to profit or loss	–4,568,680.09	–30,978,219.40	51,243,199.99	–48,333,566.35
1. Share of the other comprehensive income of the investee accounted for using equity method which will be reclassified subsequently to profit or loss	–4,568,680.09	–30,978,219.40	51,243,199.99	–48,333,566.35
VI. Total comprehensive income	485,371,001.50	304,043,422.11	1,171,123,090.61	1,017,414,580.33
VII. Earnings per share:				
(i) Basic earnings per share (yuan/share)	N/A	N/A	N/A	N/A
(ii) Diluted earnings per share (yuan/share)	N/A	N/A	N/A	N/A

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Consolidated Statement of Cash Flow

January – September 2020

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Jan – Sept 2020	Jan – Sept 2019
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	22,517,884,544.13	21,655,886,335.03
Refund of taxes and levies	228,477,946.42	181,938,713.48
Other cash received relating to operating activities	645,111,165.67	473,120,676.89
Sub-total of cash inflow generated from operating activities	23,391,473,656.22	22,310,945,725.40
Cash paid for purchasing goods and receiving services	9,605,985,955.00	7,899,513,858.29
Cash paid to and on behalf of employees	3,949,473,549.67	3,513,316,315.77
Cash paid for all types of taxes	1,802,113,214.53	1,987,996,156.33
Other cash paid relating to operating activities	5,580,765,417.02	6,581,763,610.84
Sub-total of cash outflow generated from operating activities	20,938,338,136.22	19,982,589,941.23
Net cash flow generated from operating activities	2,453,135,520.00	2,328,355,784.17
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	962,753,233.12	1,091,156,660.35
Cash received from returns on investments	570,952,515.21	547,605,619.99
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	6,561,242.60	35,482,068.71
Net cash received from disposal of subsidiaries and other operating segments	—	3,409,710.63
Other cash received relating to investing activities	109,054,243.33	733,863,748.49
Sub-total of cash inflow generated from investing activities	1,649,321,234.26	2,411,517,808.17
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	3,271,491,424.45	2,865,016,735.54
Cash paid for investments	969,647,732.90	474,828,641.34
Net cash paid for acquisition of subsidiaries and other operating segments	40,563,311.38	707,546,724.68
Other cash paid relating to investing activities	952,004,777.70	924,369,082.16
Sub-total of cash outflow generated from investing activities	5,233,707,246.43	4,971,761,183.72
Net cash flow generated from investing activities	-3,584,386,012.17	-2,560,243,375.55

Consolidated Statement of Cash Flow (Continued)

January – September 2020

Items	Jan – Sept 2020	Jan – Sept 2019
III. Cash flow generated from financing activities:		
Cash received from capital contribution	80,093,059.40	2,975,118,171.03
Including: Cash received by subsidiaries from investments of non-controlling interests	80,093,059.40	2,975,118,171.03
Cash received from borrowings	12,581,404,305.72	8,596,315,233.75
Other cash received relating to financing activities	13,487,706.36	49,944,000.92
Sub-total of cash inflow generated from financing activities	12,674,985,071.48	11,621,377,405.70
Cash paid for debts settlement	8,918,752,402.99	6,760,545,407.43
Cash paid for the distribution of dividends, profits or interest	1,944,125,870.73	1,765,161,894.66
Including: Dividends and profits paid by subsidiaries to non-controlling interests	341,049,830.97	190,472,777.69
Other cash paid relating to financing activities	1,878,322,235.94	431,687,464.08
Sub-total of cash outflow generated from financing activities	12,741,200,509.66	8,957,394,766.17
Net cash flow generated from financing activities	-66,215,438.18	2,663,982,639.53
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-132,918,882.81	47,762,255.60
V. Net increase of cash and cash equivalents	-1,330,384,813.16	2,479,857,303.75
Plus: Opening balance of cash and cash equivalents	8,284,371,152.04	7,175,005,107.37
VI. Closing balance of cash and cash equivalents	6,953,986,338.88	9,654,862,411.12

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

Statement of Cash Flow of the Parent Company

January – September 2020

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	Jan – Sept 2020	Jan – Sept 2019
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	3,728,726.62	5,149,342.00
Refund of taxes and levies	—	—
Other cash received relating to operating activities	114,534,180.91	128,222,247.72
Sub-total of cash inflow generated from operating activities	118,262,907.53	133,371,589.72
Cash paid for purchasing goods and receiving services	—	—
Cash paid to and on behalf of employees	102,071,662.06	167,820,218.62
Cash paid for all types of taxes	37,560,868.24	28,739,071.01
Other cash paid relating to operating activities	56,982,249.98	24,225,610.78
Sub-total of cash outflow generated from operating activities	196,614,780.28	220,784,900.41
Net cash flow generated from operating activities	-78,351,872.75	-87,413,310.69
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	65,884,959.55	2,700,000.00
Cash received from returns on investments	672,593,975.62	559,642,923.39
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	281,500.00	119,450.00
Net cash received from disposal of subsidiaries and other operating segments	—	—
Other cash received relating to investing activities	—	—
Sub-total of cash inflow generated from investing activities	738,760,435.17	562,462,373.39
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,175,399.99	588,665.00
Cash paid for investments	131,105,177.61	201,134,710.66
Net cash paid for acquisition of subsidiaries and other operating segments	—	—
Other cash paid relating to investing activities	—	—
Sub-total of cash outflow generated from investing activities	132,280,577.60	201,723,375.66
Net cash flow generated from investing activities	606,479,857.57	360,738,997.73

Statement of Cash Flow of the Parent Company (Continued)

January – September 2020

Items	Jan – Sept 2020	Jan – Sept 2019
III. Cash flow generated from financing activities:		
Cash received from capital contribution	—	—
Cash received from borrowings	6,227,808,000.00	5,568,766,507.00
Other cash received relating to financing activities	8,374,711,260.81	6,954,926,338.94
Sub-total of cash inflow generated from financing activities	14,602,519,260.81	12,523,692,845.94
Cash paid for debts settlement	4,917,282,400.00	3,883,257,655.50
Cash paid for the distribution of dividends, profits or interest	1,359,956,597.26	1,179,657,342.95
Other cash paid relating to financing activities	9,281,176,261.13	7,370,819,258.74
Sub-total of cash outflow generated from financing activities	15,558,415,258.39	12,433,734,257.19
Net cash flow generated from financing activities	-955,895,997.58	89,958,588.75
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-700,928.75	-26,475.30
V. Net increase of cash and cash equivalents	-428,468,941.51	363,257,800.49
Plus: Opening balance of cash and cash equivalents	515,360,096.42	455,240,544.03
VI. Closing balance of cash and cash equivalents	86,891,154.91	818,498,344.52

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Chen Zhanyu

4.2 Information on adjustments to the initial implementation of relevant items in financial statements at the beginning of the year for the initial implementation of New Financial Instruments Standards, New Income Standards and New Lease Standards

Not applicable

4.3 Explanation on retrospective adjustments to previous comparative data for the initial implementation of New Financial Instruments Standards and New Lease Standards

Not applicable

4.4 Audited report

Not applicable